A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT05923008 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: IBI130

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.